Gilead Sciences (GILD) – Research Analysts’ Recent Ratings Updates

Gilead Sciences (NASDAQ: GILD) has recently received a number of price target changes and ratings updates:

• 2/25/2026 – Gilead Sciences had its price target raised by Daiwa Securities Group Inc. from $129.00 to $161.00. They now have an “outperform” rating on the stock.
• 2/23/2026 – Gilead Sciences had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $170.00 price target on the stock.
• 2/20/2026 – Gilead Sciences is now covered by Barclays PLC. They set an “equal weight” rating and a $155.00 price target on the stock.
• 2/19/2026 – Gilead Sciences was upgraded by Barclays PLC to “hold”.
• 2/19/2026 – Gilead Sciences had its price target raised by Argus from $135.00 to $165.00. They now have a “buy” rating on the stock.
• 2/18/2026 – Gilead Sciences had its price target raised by Mizuho from $140.00 to $170.00. They now have an “outperform” rating on the stock.
• 2/17/2026 – Gilead Sciences had its price target raised by Rothschild & Co Redburn from $159.00 to $170.00. They now have a “buy” rating on the stock.
• 2/12/2026 – Gilead Sciences had its price target raised by Wolfe Research from $155.00 to $170.00. They now have an “outperform” rating on the stock.
• 2/11/2026 – Gilead Sciences had its “outperform” rating reaffirmed by Sanford C. Bernstein. They now have a $160.00 price target on the stock.
• 2/11/2026 – Gilead Sciences was given a new $162.00 price target by Bank of America Corporation. They now have a “buy” rating on the stock.
• 2/11/2026 – Gilead Sciences had its price target raised by Leerink Partners from $146.00 to $148.00. They now have an “outperform” rating on the stock.
• 2/11/2026 – Gilead Sciences had its price target raised by Oppenheimer Holdings, Inc. from $128.00 to $165.00. They now have an “outperform” rating on the stock.
• 2/11/2026 – Gilead Sciences had its price target raised by Deutsche Bank Aktiengesellschaft from $135.00 to $155.00. They now have a “buy” rating on the stock.
• 2/11/2026 – Gilead Sciences had its price target raised by TD Cowen from $145.00 to $160.00. They now have a “buy” rating on the stock.
• 2/11/2026 – Gilead Sciences had its price target raised by Royal Bank Of Canada from $103.00 to $118.00. They now have a “sector perform” rating on the stock.
• 2/11/2026 – Gilead Sciences had its price target raised by Truist Financial Corporation from $145.00 to $152.00. They now have a “buy” rating on the stock.
• 2/11/2026 – Gilead Sciences had its price target raised by Wells Fargo & Company from $150.00 to $165.00. They now have an “overweight” rating on the stock.
• 2/11/2026 – Gilead Sciences had its price target raised by JPMorgan Chase & Co. from $150.00 to $160.00. They now have an “overweight” rating on the stock.
• 2/11/2026 – Gilead Sciences had its price target raised by Morgan Stanley from $150.00 to $171.00. They now have an “overweight” rating on the stock.
• 2/11/2026 – Gilead Sciences had its price target raised by Cantor Fitzgerald from $135.00 to $155.00. They now have an “overweight” rating on the stock.
• 2/11/2026 – Gilead Sciences had its price target raised by Scotiabank from $140.00 to $177.00. They now have a “sector outperform” rating on the stock.
• 2/11/2026 – Gilead Sciences had its price target raised by Needham & Company LLC from $140.00 to $170.00. They now have a “buy” rating on the stock.
• 1/30/2026 – Gilead Sciences had its price target raised by Leerink Partners from $114.00 to $146.00. They now have an “outperform” rating on the stock.
• 1/29/2026 – Gilead Sciences had its price target raised by TD Cowen from $125.00 to $145.00. They now have a “buy” rating on the stock.
• 1/28/2026 – Gilead Sciences had its price target raised by Wolfe Research from $150.00 to $155.00. They now have an “outperform” rating on the stock.
• 1/27/2026 – Gilead Sciences had its price target raised by Truist Financial Corporation from $140.00 to $145.00. They now have a “buy” rating on the stock.
• 1/27/2026 – Gilead Sciences had its price target raised by Citigroup Inc. from $140.00 to $156.00. They now have a “buy” rating on the stock.
• 1/26/2026 – Gilead Sciences had its price target raised by UBS Group AG from $145.00 to $155.00. They now have a “buy” rating on the stock.
• 1/26/2026 – Gilead Sciences had its price target raised by BMO Capital Markets from $135.00 to $150.00. They now have an “outperform” rating on the stock.
• 1/23/2026 – Gilead Sciences was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 1/22/2026 – Gilead Sciences had its “buy (b)” rating reaffirmed by Weiss Ratings.
• 1/20/2026 – Gilead Sciences had its price target raised by Rothschild & Co Redburn from $153.00 to $159.00. They now have a “buy” rating on the stock.
• 1/20/2026 – Gilead Sciences had its price target raised by Royal Bank Of Canada from $100.00 to $103.00. They now have a “sector perform” rating on the stock.
• 1/15/2026 – Gilead Sciences had its “buy” rating reaffirmed by UBS Group AG.
• 1/13/2026 – Gilead Sciences had its “outperform” rating reaffirmed by BMO Capital Markets.
• 1/13/2026 – Gilead Sciences had its price target lowered by Morgan Stanley from $151.00 to $150.00. They now have an “overweight” rating on the stock.
• 1/8/2026 – Gilead Sciences had its price target lowered by Royal Bank Of Canada from $105.00 to $100.00. They now have a “sector perform” rating on the stock.
• 1/8/2026 – Gilead Sciences had its price target raised by The Goldman Sachs Group, Inc. from $110.00 to $115.00. They now have a “neutral” rating on the stock.
• 1/7/2026 – Gilead Sciences had its price target raised by Citigroup Inc. from $135.00 to $140.00. They now have a “buy” rating on the stock.
• 1/7/2026 – Gilead Sciences is now covered by UBS Group AG. They set a “buy” rating and a $145.00 price target on the stock.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.3%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend is Friday, March 13th. Gilead Sciences’s dividend payout ratio is currently 46.68%.

Insider Activity

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $154.44, for a total transaction of $4,324,320.00. Following the sale, the insider directly owned 120,288 shares of the company’s stock, valued at $18,577,278.72. This trade represents a 18.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $144.79, for a total value of $1,447,900.00. Following the completion of the transaction, the chief executive officer directly owned 642,308 shares of the company’s stock, valued at approximately $92,999,775.32. This trade represents a 1.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 309,280 shares of company stock valued at $43,935,470 over the last 90 days. Company insiders own 0.27% of the company’s stock.

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.